On the afternoon of October 23, 2025, toEmpowering Biological Efficacy and Safety EvaluationThe high-throughput microplate detection system technology exchange meeting with the theme was successfully held at the Jinji Lake Roadshow Center in Suzhou. This event was jointly presented by Meigu Molecular Instruments (Shanghai) Co., Ltd. and Aibo Kang (Shanghai) Trading Co., Ltd., attracting numerous representatives of biopharmaceutical companies, R&D and quality experts to discuss cutting-edge detection technologies and compliance practices in drug discovery and safety evaluation.

Market Manager of Meigu Molecular Instruments ProductsYin DiLeading the way in bringingBreaking through the limits of detection and empowering compliant data analysisThe sharing. Starting from practical applications, he guided the audience to cross the boundaries of traditional detection methods, introduced in depth the application scenarios of various advanced detection technologies, and demonstrated on site how to use SoftMax Pro software to achieve efficient and reliable data analysis in a compliant environment.

Aibo Kang Strategic Market ManagerSu QianInEmpowering Biopharmaceutical Development and Optimizing Bioanalytical PK/PD EvaluationThe report points out that reliable and consistent analysis data is the key to driving drugs from research and development to market. She shared how to improve the quality and efficiency of PK/PD research through cutting-edge biological analysis methods, based on industry trends and technological practices, to assist in the efficient development of biopharmaceuticals.

Director of Applied Scientists at Meigu Molecular InstrumentsLiu XuanThe finale, revolving aroundEmpowering Pharmacopoeia with New Standards, Intelligent Testing ComplianceExpand deep analysis. With the full implementation of the new version of the Chinese Pharmacopoeia, he focused on the analysis and application of enzyme-linked immunosorbent assay (ELISA) under the new regulations, interpreted in detail the statistical methods in General Rule 1431 and Guiding Principle 9401, and combined with the actual operation of SoftMax Pro 7. x GXP compliance software, provided a practical path for the on-site audience to cope with the challenges of the new standards.

SoftMax Pro software

About Meigu Molecular Instrument

Molecular Devices was founded in Silicon Valley, USA in the 1980s and has multiple representative offices and subsidiaries worldwide. In 2005, Molecular Devices established a representative office in Shanghai, joined Danaher Group, a global innovator in science and technology, in 2010, and officially established a business company in 2011: Meigu Molecular Instruments (Shanghai) Co., Ltd. Molecular Devices is renowned in the industry for its continuous innovation, fast, efficient, high-performance products, and comprehensive after-sales service. We have been committed to providing customers with innovative biological analysis solutions in protein and cell biology in the fields of life science research, pharmaceutical and biological therapy development.